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Abstract: New molecular insight reveals novel points of attack for targeted cancer therapy. The recent advances in cancer ge-
nomics and novel insight into the complex biology of cancer make the promise of personalized, targeted cancer medicine closer
than ever. The massive parallel sequencing endeavours performed by The Cancer Genome Atlas, the International Cancer Gen-
ome Consortium and by numerous individual investigators have provided a comprehensive genomic characterization of a wide
range of cancers. The joint efforts enabled by the improved sequencing technology have demonstrated that individual cancers
comprise mutational repertoires with only a few frequently recurrent driver genes. Thus, the identification of new drug targets
and novel drugs have accelerated and renewed the hopes of personalized cancer therapy achieving clinical reality for a wider
range of cancers. Together with cost-effective sequencing technology to perform comprehensive mutational profiling of each indi-
vidual cancer, this provides the basis for a personalized cancer medicine revolution within the next few years. The aim of this
MiniReview is to provide an overview of the history and evolution of targeted cancer therapy, exemplified by molecularly tar-
geted drugs successfully implemented in the clinic. Furthermore, we aim to highlight novel molecular targets for therapeutic
intervention, as well as the main present challenges including inter- and intratumor heterogeneity and cellular plasticity in addi-
tion to the importance of the tumor micro-environment. Many cancer patients already receive some form of tailored therapy, and
recent evidence suggests that novel and highly innovative, targeted approaches are on their way into the clinic.
There is an old adage that cancer is a hundred diseases masquer-
ading into one. In support of this, Hanahan and Weinberg have
defined several hallmarks of cancer, common to most, if not all,
cancers [1]. Application of improved DNA sequencing technol-
ogies developed during the Human Genome Project (HGP) has
confirmed and extended this adage, revealing the fact that even
within a single cancer group or subgroup, each cancer has a
unique genetic make-up. New technology, availability and low-
ered sequencing costs, allow wider application and provide can-
cer researchers and clinicians with a comprehensive
compendium of the genetic alterations present within an individ-
ual tumor sample. Indeed, recent findings from The Cancer
Genome Atlas (TCGA) and the International Cancer Genome
Consortium (ICGC) have further verified that although each
cancer seems to be unique in its repertoire of genetic mutations,
a range of signaling pathways are frequently affected within par-
ticular cancer types [2]. The present challenge is to filter the
genetic alterations ‘driving’ tumor progression from the ‘passen-
gers’, also referred to as ‘noise’ present due to extensive geno-
mic instability. Ongoing efforts to detect alterations driving
tumor progression can be identified at accelerated speed both
within and across cancer subtypes. Integrated multi-disciplinary
efforts combining insight into the underlying molecular pro-
cesses, not only within a particular form of cancer, but also
across different kind of cancers, is required to meet the expecta-
tions of development of tailored cancer treatment. Hopes are
high that along with an improved molecular characterization,
accelerated development of molecularly targeted drugs will pro-
vide the tools required to enable oncologists to tailor cancer
treatment to the individual cancer patient based on tumor char-
acteristics.
Oncology is a major field of focus for pharmaceutical and
biotechnology companies. This interest stems from the unmet
need for improved treatments of multiple types of cancer, as
well as from the substantial market success of targeted cancer
therapies launched in the past decade [3]. Targeted cancer
therapies are drugs that are designed to address the genetic
alterations required for cancer growth and progression and
thereby prevent the survival, growth and spread of cancer
cells. From a scientific point of view, specific alterations dis-
tinguishing cancer cells from normal cells may be referred to
as molecular targets, and therapies that interfere with them are
called targeted drugs or targeted therapies. Unlike conven-
tional cancer therapies, targeted cancer therapies are designed
to address specific molecular alterations harbored within a
particular cancer. Targeted cancer therapies that have been
approved for use in specific cancers include drugs that pro-
mote cancer cell death by interfering with cellular survival sig-
naling, as well as specific targets responsible for maintaining
supportive tumor micro-environment. The latter may be
referred to as re-education of the micro-environment and can
comprise attempts to prevent formation of tumor vasculature
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and stimulation of the immune system to attack and destroy
cancer cells. Unlike traditional cytotoxic chemotherapies that
have frequently entered the clinic without exact knowledge of
their mechanism of action and have been discovered and
developed on the basis of their ability to interfere with cell
division, molecularly designed drugs, on the other hand, have
been developed based on a particular known molecular target.
Thus, a primary goal of molecularly targeted cancer therapies
is to fight cancer with more precision than traditional chemo-
therapy regimens and hopefully with the additional benefit of
less adverse side effects for the patient in treatment. It should
be noted, however, that side effects of some molecularly tar-
geted US Food and Drug Administration (FDA) approved
drugs are not insignificant, and neither are the treatment costs,
highlighting the importance of identifying reliable biomarkers
to predict which patients will benefit from a particular treat-
ment. Of note, most targeted therapy approaches are currently
being tested within standard-of-care treatment protocols and
will thus primarily function as a supplement to available treat-
ment regimens. In addition, by combining molecularly targeted
therapies with current standard-of-care, it is suggested that the
efficacy of available treatment regimens will improve and may
further reduce the risk of relapse and metastatic disease. Thus,
targeted cancer therapy is suggested to be important in the
management of cancers that are currently considered incurable,
in a strategy where the aim is to keep the cancer under control
and increase progression-free survival for prolonged periods of
time, or even for the life-time of the patient.
Parameters such as histological grade and gene expression
profiles may provide moderate statistical correlates to out-
come, but do not define biological targets for therapeutic inter-
vention. To make an analogy to clothes manufacturing;
everybody spots the difference between having a full tailor-
made suit or dress versus simply cutting a few centimetres of
the length of some readymade garment to make it fit your
length [4]. In parallel, targeted or tailor-made therapy should
not be confused with implementing simple prognostic or pre-
dictive factors. These parameters, in general, do not define
direct biological targets, but rather biological parameters
revealing a variable statistical correlation to outcome [4]. Tak-
ing the analogy of clothes manufacturing, the definition of tai-
lored therapy should implement targeted therapies based on
identification of individual therapeutic targets such as HER2
[5] in the tumour tissue, providing a target exclusive to this
tumor for therapeutic attack [6]. Thus, targeted therapy
requires exact knowledge of a particular cancer and further
empirical knowledge of predictive biomarkers.
In theory, a similar discussion should be applied not only to
‘targeted’ therapy, but also to anticancer strategies in general,
including options like cytotoxic therapy. Some cytotoxic anti-
cancer agents could be considered ‘targeted therapy’. This is
perhaps best exemplified by the class of drugs named anthra-
cyclines (or anthracycline antibiotics), which are amongst the
most effective anticancer treatments ever developed. Anthracy-
clines are currently used in the treatment of a wide range of
both solid and haematopoietic cancers. Similar to several other
frequently used chemothera peutic agents; anthracyclines exert
their cytotoxic effects by several mechanisms, one of which is
inhibition of the topoisomerase II enzyme, thus blocking DNA
transcription and replication. A parameter like topoisomerase II
may be considered a therapeutic target per se. The fact that this
enzyme is a direct target of anthracyclines, and amplification
of its gene has been related to improved sensitivity to anthra-
cycline therapy, suggests anthracycline-based chemotherapy to
be a candidate tailored therapy for topoisomerase-II-amplified
tumors [4]. It is, however, important to notice that topoisomer-
ase II over-expression is not mandatory for anthracycline
response, and evidence regarding its predictive role remains
conflicting [7]. Thus, in this context, the use of antharcyclines
in cancer therapy is not considered ‘targeted cancer therapy’.
The vast majority of current targeted therapies are either
monoclonal antibodies or small-molecule drugs. Most mono-
clonal antibodies cannot penetrate the cell’s plasma membrane
and are directed against extracellular targets, like the ligand-
binding sites of receptors or the ligand itself. Small-molecule
drugs are typically able to diffuse into cells and thus have the
advantageous ability to act on targets localized inside the cell.
For the purpose of therapy, the monoclonal antibodies were
primarily designed to target the ligand-binding domain at a
membrane-bound receptor molecule, thus acting as an antago-
nist, preventing the ligand/receptor interaction, as well as the
activation of its downstream signalling cascade. There are cur-
rently 14 antibodies approved by the FDA for use in clinical
oncology, eight of which are indicated for solid tumours, and
six for haematopoietic cancers [8]. As the first therapeutic anti-
body, Rituximab (Rituxan/Mabthera; Novartis: Basel, Swit-
zerland) targeting the B-lymphocyte antigen, CD20, was
approved by FDA in 1997 for the use in patients suffering from
non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia
(CLL). Antibodies approved for treatment of haematological
cancers and B-cell-associated targets (CD20, CD52) act mainly
by inducing apoptosis in the target cell upon binding [9,10].
More recent antibody-based therapeutic approaches propose the
use of monoclonal antibodies as promising vehicles for the tar-
geted delivery of potent chemotherapeutic agents as well as
powerful tools to manipulate anticancer immune responses.
Small molecules are, as the name implies, defined and
restricted by their size. By definition, small molecules cannot
exceed a mass of 900 Dalton. However, a maximum size of
500 Dalton is recommended for small-molecule drug develop-
ment, due to the improved ability of smaller molecules to pen-
etrate the plasma membrane. From a pharmacological point of
view, the term ‘small molecule’ is often restricted to a com-
pound that acts as effector by binding to a specific macromol-
ecule and altering its activity and function. A macromolecule
may be a specific protein or nucleic acid. Small-molecule
inhibitors (SMIs) can be designed to inhibit a specific function
of a multi-functional protein or impede protein–protein interac-
tions. As will be discussed later in this work, the development
of small-molecule inhibitors for clinical oncology was pio-
neered by the first attempts to develop antihormonal drugs for
breast cancer.
The generic name of a targeted agent provides clues to the
type of agent and its cellular target. Briefly, monoclonal anti-
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bodies (mAbs) are denoted with the suffix ‘-mab’, while
small-molecule inhibitors end with ‘-ib’. In addition, the speci-
fication of the mAbs is included in the name, designated
‘-ximab’ for chimeric human-mouse antibodies or ‘-zumab’
for humanized mAbs and ‘-mumab’ for fully human antibod-
ies. Furthermore, depending on whether the target is circula-
tory or a tumor target, the substems ‘-ci’ or ‘-tu’ are utilized
for mAbs, whereas for small-molecule inhibitors, the stem
‘-tin’ is used for tyrosine kinase inhibitors, and ‘-zom’ is used
for proteasome inhibitors. Examples of the naming of targeted
therapies are hence cetuximab, where the tyrosine kinase is
the target, and the mAb is a human–mouse chimera. Imatinib
Mesylate (Gleevec; Novartis) is an example of a small-mole-
cule inhibitor in which a tyrosine kinase is the target. In this
MiniReview, generic names for each drug are given, with
brand name and pharmaceutical company in brackets. A com-
plete overview of targeted drugs in clinical trials can be found
at: www.clinicaltrials.com.
Targeted Therapy in Clinical Practice Directed Against
Cancer Cells
Antihormonal therapy.
The first established tailored therapy implemented in oncologi-
cal practice is the antihormonal therapy in breast cancer. Anti-
hormonal therapy is still one of the most widely used targeted
therapies, as two of three of breast cancers in post-menopausal
women are oestrogen receptor (ER) positive. Antihormonal ther-
apy works by depriving tumour cells of ligand ER activation
either by use of anti-oestrogens or through suppression of oestro-
gen synthesis by aromatase inhibitors, such as anastrozole
(Arimidex; AstraZeneca: Wilmington, DE, USA) [4]. The
widely used Tamoxifen (discovered by AstraZeneca) belongs to
the collection of drugs termed selective estrogen receptor modu-
lators (SERMs), which is a group of small-molecule inhibitors
with strong binding affinity for the oestrogen receptor, thus act-
ing as oestrogen competitors at the binding site at the oestrogen
receptor antagonizing the effect of oestrogen. The development
of antihormonal therapy for breast cancer has been reviewed
extensively elsewhere [11].
Tyrosine kinase inhibitors.
Tyrosine kinases (TKs) are a group of enzymes responsible
for the activation of multiple downstream proteins in cellular
signal transduction cascades. Activation is presented by pro-
tein phosphorylation. Tyrosine kinase inhibitors (TKIs) are
designed to inhibit the catalytic activity occurring during phos-
phorylation of the TKs. Depending on the TK of interest and
the site of target, TKIs may be designed to compete with
binding affinity of the co-enzyme energy carrier molecule ATP
or the enzyme substrate (or both), or by allosteric inhibition
resulting in unfavourable conformational changes, resulting in
blocked or reduced enzymatic activity.
TKs are frequently deregulated in cancer, and due to their
importance in maintaining survival signaling and proliferation
of cancer cells, they represent attractive targets for cancer
therapy. However, protein phosphorylations by TKs are
important regulators of cellular communication within all
cells, cellular proliferation and maintenance of both normal
and stem cell populations. Thus, targeting TKs by TKIs may
also affect non-canceros cell populations, which in turn may
result in adverse side effects. Although TKIs overall appear
to be a well-tolerated drug class, most TKIs are associated
with short-term haematological side effects like anaemia,
thrombopenia and neutropenia. The most common short-term
extra-haematologic adverse effects are oedema, nausea, hypo-
thyroidism, vomiting and diarrhoea. Regarding possible long-
term effects, use of TKI has been associated with cardiotox-
icity [12].
Targeting the Bcr-Abl fusion protein.
A unique example of a target expressed solely by cancer cells
was provided in 1960 by the discovery of the Philadelphia
chromosome in chronic myeloid leukaemia (CML). This was
the very first specific chromosomal alteration described in can-
cer [13]. Later, it was discovered that most cases of CML are
caused by the expression of the fusion protein Bcr-Abl,
encoded by the fusion gene named BCR-ABL [14]. This fusion
gene is formed when pieces of chromosome 9 (BCR) and
chromosome 22 (ABL) break off and trade places. The result-
ing fused chromosome is referred to as the Philadelphia chro-
mosome. The TK protein normally produced by the ABL gene
is a signaling molecule that plays an important role in control-
ling cell proliferation and predominantly interacts tightly with
other signaling molecules in order to be activated. However,
Abl signaling is always active when expressed in the form of
the fusion protein Bcr-Abl. Thus, the constitutive activity of
Bcr-Abl promotes continuous proliferation of CML cells, and
CML may thus be considered an oncogene addictive cancer.
As the protein Bcr-Abl is expressed solely by cancer cells, it
represents an ideal target for TKIs. Imatinib Mesylate (Glee-
vec; Novartis) was originally designed for inhibition of
PDGFR but was later identified as an efficient inhibitor of the
Abl kinase domain [15]. The introduction of a molecularly
designed drug that efficiently targeted Bcr-Abl represented a
shift in paradigm in the field of clinical oncology. As for sev-
eral other targeted drugs, Imatinib was initially launched for a
narrow indication, but its indications were later expanded to
include other malignancies. While Imatinib has been shown to
significantly limit tumour growth in CML, resistant clones,
most often caused by point mutations in the kinase domain of
Bcr-Abl, still represent a therapeutic challenge [16]. In treat-
ment of CML, Imatinib was initially replaced by more potent
second-generation drugs, Dasatinib (Sprycel; Bristol-Myerz
Squibb; New York City, NY, USA) and Nilotinib (Tasigna;
Novartis), that have proven effective for patients who have
relapsed or are refractory to treatment with Imatinib. However,
patients carrying the mutation in the Abl kinase domain T315I
are resistant to both Dasatinib and Nilotinib. A third-genera-
tion drug, Ponatinib (Iclusig; ARIAD Pharmaceuticals: Cam-
bridge, MA, USA), was shown to overcome the resistance due
to the T315I mutation in CML patients and had an accelerated
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FDA approval. However, severe side effects observed in clini-
cal trials led to the withdrawal of Ponatinib from the US mar-
ket. The history of Ponatinib highlights the importance of
implementing clinical evaluation and reliable biomarkers to
predict which patients have an elevated risk of adverse side
effects.
Targeting the epidermal growth factor receptor (EGFR).
The receptor tyrosine kinase (RTK) epidermal growth factor
receptor (EGFR) is known to be deregulated and represents a
key player in oncogenesis in several solid cancers including
non-small-cell lung carcinoma (NSCLC), head and neck can-
cer, colon cancer and glioblastoma (GMB). EGFR is aberrantly
activated by various mechanisms including amplifications and
mutations, resulting in over-expression, decreased internaliza-
tion and constitutive activation [17]. Although not unique to
cancer cells, EGFR has long been an attractive molecular target
for cancer therapy. Attempts to target EGFR have been
explored by both monoclonal antibodies, as well as small-mol-
ecule inhibitors. Unfortunately, the clinical efficacy of EGFR-
targeted therapy for some cancer types like GBM, both in the
case of antibody therapy and small-molecule inhibitors, has
shown variable levels of success and has not met its expecta-
tions. While Cetuximab (Erbitux; Bristol Myers Squibb) as
an adjuvant therapy in head and neck cancer has significantly
improved both progression-free survival and overall survival,
the majority of clinical trials implementing anti-EGFR treat-
ment in other solid cancers have failed to induce prolonged
survival [18,19]. In many cases, a temporary response to EGFR
inhibitory treatment may be observed. However, rapid tumor
re-growth and resistance to therapy are frequently seen [20].
Several explanations have been postulated to explain the lack
of response and resistance to EGFR-targeted therapy, including
mutations in the binding sites of the targeted drug, as well as
secondary effector mutations affecting downstream signaling
molecules in the EGFR-activated pathway. Secondary muta-
tions in EGFR (T790M) or up-regulation of the MET kinase
are found in over 50% of resistant tumors [21]. Moreover, in
some cancers with de-regulated EGFR, the fraction of cells
harboring alterations in the EGFR regulations varies
considerably, and this heterogeneity may further explain the
modest efficacy of anti-EGFR treatment. Importantly, for
EGFR-targeted therapy, EGFR itself may be misleading as a
biomarker for stratification to EGFR-targeted therapy, as it
often fails to predict therapeutic response [18,22]. An excellent
example is provided in the case of metastatic colon cancers,
where the downstream effectors of EGFR, such as the mutation
status of KRAS, have been implemented as a predictive bio-
marker for selection of patients to EGFR-targeted therapies
[23]. Panitumumab (Vectibix; Amgen: Thousand Oaks, CA,
USA) was approved by the FDA in 2006 and was the first anti-
body directed against EGFR to demonstrate the use of KRAS
as a predictive biomarker. Later, in 2009, Cetuximab was
approved by the FDA for the use in KRAS wild-type, EGFR-
expressing, metastatic colorectal cancer in combination with
Irinotecan (topoisomerase I inhibitor)-based chemotherapy
regimens [24]. In addition to KRAS mutations, which accounts
for 35–40% of resistant cases, also NRAS mutations, B-RAF
mutations [25], mutations in PI3KCA [26] and inactivation of
PTEN [27] have been shown to contribute to anti-EGFR resis-
tance in several cancers. Implementation of these and other
predictive biomarkers in clinical trials validating anti-EGFR
treatment may significantly improve the clinical trial design.
Interestingly, the presence of the RTK AXL has been shown to
limit the response of EGFR-targeted inhibitors in NSCLC [28]
and ErbB2/Her-2 inhibitors in triple-negative breast cancer
cells [29], thus identifying AXL as a promising therapeutic tar-
get for overcoming resistance to TKIs targeting members of
the EGFR family of TKs. The identification of potential bio-
markers and resistance mechanisms may further aid in the
development of new potential targets for therapy, as seen in the
case of NSCLC, where AXL were found to be over-expressed
in the therapy-resistant clones. Since this breakthrough discov-
ery, AXL was further suggested as an applicable target [28],
and the first-in-class AXL inhibitor BGB324 is now entering
clinical trials [30].
Targeting HER-2.
In the case of solid cancers, the first molecularly targeted
antibodies directed at epitopes of the cancer cells themselves
were anti-EGFR (ErbB1) and anti-HER2 (ErbB2), transmem-
brane RTKs. Contrasting the partially unmet potential of
EGFR-targeted therapies, HER-2 targeted therapies have rev-
olutionized the treatment of the 15–30% of breast cancers
harboring amplification of the ERBB2 gene or over-expres-
sion of the HER-2 protein [31]. In the era prior to HER-2-
targeted therapies, ERBB2-amplified breast cancers were
associated with a particularly poor prognosis. Trastuzumab
(Herceptin; Genentech: San Fransisco, CA, USA), a
humanized mAb interfering with the HER2/Neu receptor,
was approved by the FDA in 1998 and has since then had
a major impact on the treatment of HER2-positive breast
cancers as an adjuvant therapy. Early stages of HER-2-posi-
tive breast cancers (stage 0–3) respond well to Trastuzumab,
and importantly, 50% of these cases do not develop recur-
rent tumors. Furthermore, in a phase-III study of HER2-
positive stage 4 (metastatic) breast cancers, Trastuzumab
increased the overall survival (OS) from 20 to 25 months
[32]. However, in the case of metastatic breast cancer,
innate resistance or acquired resistance, which does eventu-
ally occur in virtually all cases, points at a major challenge
common to all kinds of oncology treatment. Recently, how-
ever, a differently modified version of trastuzumab, referred
to as trastuzumab emtansine (T-DM1, Kadkyla; Genen-
tech), has been approved as targeted therapy for HER2-posi-
tive metastatic breast cancers [33]. T-DM1 qualifies as an
antibody-drug conjugate (ADC) as it is a covalently modi-
fied cytotoxic microtubule antagonist and thus represents a
form of targeted chemotherapy. Recent and ongoing phase
III clinical trials including T-DM1 present significantly pro-
longed PFS and OS [34]. Importantly, these results show
for the first time that an antibody conjugate alone can be
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more effective than standard chemotherapy with Doxetaxel
plus Trastusumab as a first-line treatment for metastatic
HER-2-positive breast cancer [34]. In addition to a higher
tumor response rate, there was significantly better disease
control as well as significantly fewer adverse side effects.
Based on the recent success accomplished with T-DM1,
multiple ADCs are currently in clinical development.
Targeted Therapy Directed at the Micro-environment
During the past few years, it has become increasingly evident to
acknowledge the importance of the stromal contribution to can-
cer initiation and progression. The complex intercommunication
between tumor and micro-environment is obvious in all stages
of cancer and may represent a unique niche in which novel
molecular markers and targets for therapy have yet to be identi-
fied. Several studies have revealed that the micro-environment
is capable of normalizing tumor cells, suggesting that re-educa-
tion of the stromal compartment, rather than targeted ablation
per se, may be an effective strategy for treating cancer [35]. Fur-
thermore, including direct intracellular changes, the initiation
and progression of a tumor are dependent on intercellular con-
tact, both with neighbouring cancer cells and normal cells com-
posing the micro-environment. Components of tumor stroma
include cancer-associated fibroblasts, various cells of the
immune system and vasculature. It has been postulated that
mechanisms of therapy resistance are conferred primarily by
alterations in the tumor micro-environment [36]. The most
prominent component of the tumor stroma is perhaps the vascu-
lature. In 2004, Bevacizumab (Avastin; Genentech/Roche), the
only FDA-approved therapeutic antibody directed against the
secreted vascular endothelial growth factor (VEGF), was
approved by the FDA for use in several different cancers. VEGF
is considered as a key pro-angiogenic factor, required for the
sprouting of blood vessels, a physiological process termed
angiogenesis. Angiogenesis is a hallmark of cancer [1], fre-
quently associated with a poor prognosis, and thus, targeting the
formation of tumor vasculature represents an attractive area for
targeted cancer therapy. Unfortunately, in clinical trials, the
treatment efficacy of Bevacizumab has been rather disappoint-
ing. However, as seen in the case of metastatic colorectal can-
cer, Bevacizumab provided a 2.5-month survival advantage
when used in combination with the chemotherapy regimen
FOLFOX4 (Oxaliplatin (Elxatin; Sanofi-Aventis: Bridgewater,
NJ, USA) plus Leucovorin plus 5-fluorouracil) [37]. Bev-
acizumab has further been implemented in the treatment of
recurrent GBM, a highly angiogenic grade-IV brain tumour,
where it has been shown to reduce oedema and relieve intracra-
nial pressure. However, it has not been associated with an
increase in OS. Two recent reports in NEJM, the AVAglia report
[38] and RTOG 0825 [39] trials, address the clinical benefit of
adding Bevacizumab to the best standard treatment for newly
diagnosed GBM. The trials both show prolongation of PFS, but
did, however, not translate into an increase in OS [38].
Although numerous attempts have been made to identify reli-
able predictive biomarkers for Bevacizumab, so far no reliable
and reproducible biomarker have been identified [40] (fig. 1).
As for the tumor micro-environment at large, the process of
vascularization is complex, and a panel of selected drugs may
be needed in order to efficiently inhibit formation of new
blood vessels supplying nutrients and oxygen to the growing
tumors. Alternative therapeutic approaches for targeting tumor
vascularization includes blocking of the pro-angiogenic recep-
tors including VEGFRs and PDGFR (Sorafinib Tosylate
(Nexavar; Bayer and Onyx Pharmaceuticals: San Fransisco,
CA, USA), Sunitinib Malate (Sutent; Pfizer: New York City,
NY, USA) – both of which are approved by the FDA for vari-
ous cancers in specific therapeutic windows. As in the case of
EGFR, the process of vascularization is not unique for tumori-
genesis, and the risk of severe adverse events including seri-
ous soft-tissue and vascular toxicities may present [41].
However, while the anti-angiogenic strategies have not ful-
filled their expectations, preclinical and initial clinical evi-
dence reveals that normalization of the abnormal tumor
vasculature is emerging as a complementary therapeutic para-
digm, as it may recreate a normal blood flow and thus
increase the efficacy of other radiotherapy and systemically
delivered anticancer treatments [42]. Tumor micro-environ-
ment is a field of intense study, and the importance of inflam-
mation in tumor initiation and progression has been
highlighted in recent studies. In the cases of chronic inflam-
matory diseases, multiple targeted agents inhibiting pro-
inflammatory cytokines are currently approved for clinical
administration. Importantly, numerous pro-inflammatory cyto-
kines have also been verified as potent pro-angiogenic factors,
suggesting promising therapeutic interventions by implement-
ing targeted anti-inflammatory agents in existing cancer treat-
ment regimens [43,44]. Currently, several drugs inhibiting
integrin activation are implemented in clinical trials and may
in addition improve anti-angiogenic, as well as anti-invasion
and antimigratory therapy [45]. As previously mentioned, acti-
vation of the AXL kinase has shown to be a predictive bio-
marker for anti-EGFR therapy resistance [46]. AXL is
associated with poor prognosis for many kinds of cancers,
including breast, NSCLC and GBMs, mediating the event of
epithelial to mesenchymal transition, stemness, as well as
survival, cell proliferation and chemo resistance. Interestingly,
recent studies have provided evidence indicating that the
ligand for AXL, growth arrest-specific gene 6 (GAS6), is
mainly produced by bone-marrow-derived stem cells (BDSC)
[47]. This paracrine axis between AXL-GAS6 highlights the
importance of intercellular communication and regulated con-
nection between cancer cells and the surrounding micro-envi-
ronment. Furthermore, AXL-targeted drugs have been shown
to improve the anti-EGFR drug sensitization and may thus
represent another promising candidate for personalized medi-
cine [47].
Therapies Activating Immune Response
The theory of immune surveillance was first conceptualized in
the early 1900s by Paul Erlich. He suggested that cancer cells
frequently arise in the body, but are recognized as foreign and
efficiently eliminated by the immune system. Some 50 years
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later, Burnet and Thomas suggested that the cell-mediated
branch of the immune system had evolved to patrol the body
and eliminate cancer cells. According to these concepts, can-
cers arise only if the cancer cells are able to escape immune
surveillance, either by reducing their expression of tumor anti-
gen or by impairment in the immune response to these cells,
or both. However, despite the theory proposed by Burnet and
Thomas concerning immune surveillance, the significance of
the immune system in patrolling the body and preventing can-
cer initiation and progression remained controversial, until the
important work by Schreiber and colleagues in 2011 [48],
demonstrating that the immune system can, and often does
prevent tumors from developing, and thus that the immune
system plays an important role in protecting the organism
against the development and progression of cancer [49]. This
work established that tumour cells are indeed recognized and
destroyed through immune surveillance. However, some tumor
cells may evolve to avoid recognition by the immune system,
through a process referred to as immune editing [48].
Clinically, it is known that tumors can remain dormant and
asymptomatic in patients for years or even decades before they
become clinically apparent and that patients appearing to be in
full remission still may have tumor cells circulating in their
blood, which may cause cancer relapse. Thus, a promising
therapeutic strategy like re-activating the immune system to
target the cancer cells may synergize with standard-of-care
therapy to keep tumors in dormancy for prolonged periods of
time to prevent relapse and metastatic spread of tumors [35].
The very idea behind cancer immunotherapy is to induce a tar-
geted immune response against cancer cells [50]. Evidence is
now accumulating on the issue of various effects of immune
cells infiltrating cancers, and infiltration of T cells is for many
cancers the most prominent prognostic factor, and thus, the
mechanisms underlying differences in immune status amongst
cancer patients are currently being investigated [51]. The first
approved immune checkpoint blockade therapy was the
CTLA4 blocking antibody Ipilimumab (Yervoy; Bristol-
Myers Squibb). The FDA approval of Ipilimumab in 2011 rep-
resents a breakthrough in the field of immunotherapy, as well
as a new therapeutic paradigm for cancer. Actually, the study
A B
Fig. 1. Targeted cancer therapies directed at targets within the cancer cells or micro-environmental targets. Targeted therapy is currently focused on
(A) tumor micro-environmental targets such as (1) angiogenic blood vessels (e.g. Bevacuzimab) and (2) re-education of the immune system (e.g. I-
pilimumab), or (B) targets on the cancer cells themselves. Targeting cancer cell signaling pathways include (3) targeting extracellular domains of
transmembrane receptors (e.g. Cetuximab and Trastuzumab) or (4) intracellular targets, such as TK domains and downstream signaling (e.g. Imati-
nib). Furthermore, intracellular targets also comprise nuclear signaling (5 and 6; e.g. SERMs). As highlighted in this figure, alternative biomarkers
may either be expressed by cells composing tumor micro-environment or by the tumor cells, and importantly, cancer biomarkers may differ from
the target itself.
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by Hodi and coworkers was the first report in 10 years to
show improved survival in patients with malignant melanoma
[52]. Elevated expression of the cytotoxic T-lymphocyte-asso-
ciated antigen 4 (CTLA4) in cancer cells suppresses the
immune system by down-regulating the amplitude of T-cell
activation [52]. By targeting the immunological synapse
immune checkpoint CTLA4, Ipilimumab allows for a re-acti-
vation of the patient’s own immune system to fight cancer
cells. Although Ipilimumab induces long-lasting clinical
responses in about 10% of melanoma patients, it is associated
with severe side effects, again highlighting the need for reli-
able predictive biomarkers.
New Development of Targeted Cancer Therapy
From a researcher point of view, the century of 2000 was ini-
tiated with the access to the unique data set produced in the
HGP, allowing complete insight into the sequence of every
human gene, acknowledging, for the first time, the complete
genetic blueprint of the human body. This project has had
great implications in multiple aspects of research, ranging
from evolution to molecular medicine. In 2003, the project
was completed, and the enormous data set obtained from HCP
is available online and represents a unique tool for character-
ization of the genomic changes occurring in the initiation and
progression of cancer. In the wake of the HGP, efforts of the
Cancer Genome Association (TCGA; cancergenome.nih.gov/)
and ICGG (http://icgc.org/) provide complete characterization
of cancer genomes. TCGA is a consortium initiated in 2005
aiming to describe and catalogue genetic changes in a panel of
different cancers by combining high throughput techniques
and bioinformatic tools. TCGA is supervised by a cooperation
of the National Cancer Institute and the National Human Gen-
ome Research Institute, funded by the US government. In
2006, TCGA initiated a 3-year pilot project with the aim of
characterizing three types of cancers, namely GBM, NSCLC
and ovarian cancer, by the use of high throughput techniques
including gene expression profiling, copy number variation
profiling, small nucleotide polymorphisms (SNP) genotyping,
genome-wide DNA methylation profiling, microRNA profiling
and exon sequencing. The consortium has now revealed
detailed genomic signatures of numerous cancer types [2].
Clearly, various research groups had already established many
of the genomic alterations identified by the TCGA. However,
as well as providing statistically relevant information of estab-
lished genetic alterations in cancers, the TCGA share detailed
information of additional genetic changes that can be used by
cancer researchers throughout the world. Complementing the
data sets obtained on a panel of different cancer types, the
TCGA has published a unique data set in 2013, referred to as
the pan-cancer initiative analysis project where they compare
the first 12 tumor types that were profiled. Primary cancers
included in the pan-cancer initiative were GBM, acute myeloid
leukaemia (AML), head and neck cancer, squamous cell can-
cer, as well as breast-, lung-, kidney-, ovarian-, bladder-,
colon-, rectal-, cervical- and endometrial adenocarcinomas.
Undoubtedly, these findings will be of great importance in the
search for finding common genetic signatures across cancer
types [2]. Hopes are high that the massive parallel sequencing
efforts may provide clues on how to overcome resistance to
targeted therapies across different cancer types. If, or when,
deep sequencing technologies are implemented in the clinic, it
may be possible to predict whether a particular cancer will
respond to a given treatment and thus allow the oncologist to
tailor-make the treatment to the individual cancer patient. A
key point is that exomic sequencing needs to be conducted
together with analysis of gene expression and transcriptomic
alterations by, for example, RNA sequencing, to detect
whether the genomic alterations predicted by DNA sequencing
are actually expressed. Furthermore, as cancer cells frequently
exhibit genomic instability and epigenetic changes such as
aberrant methylation and altered transcription factor binding,
mapping of epigenetic alterations and analysis of gross chro-
mosomal rearrangements should also be included in a com-
plete cancer genomics analysis. Of particular importance is the
establishment of comprehensive bio-banks containing not only
tumor tissue, but in addition, information regarding how each
particular tumor responds to defined treatment regimens,
whether the tumor gave rise to metastases and information
regarding time to progression and survival. By comparing bio-
logical information with clinical outcome, we enable identifi-
cation of common denominators responsible for specific
malignant phenotypes. The clinically important issue of drug
resistance may be best studied in clinically relevant tumor
models and further in prospectively designed clinical trials.
With regard to the clinical challenge of metastasis, tumor
bio-banks should further be expanded to include analyses of
not only primary tumors but also metastatic/recurrent lesions
or circulating tumor cells (CTC) and disseminated tumor cells
(DTC). The focus of CTC, DTC or metastatic lesions is partic-
ularly important as we know that it is the metastatic spread of
a small population of tumor cells that eventually may compro-
mise a normal tissue or organ and are responsible for most
cancer-related deaths.
Recent advances in sequencing technology have overcome
the limitations of cost and scale, and thousands of somatic
mutations can now be identified in a single cancer sample
even when several mutational processes are operative [2].
Massive parallel sequencing combined with various bioinfor-
matic algorithms can aid in further exploration of the land-
scape of mutational signatures and possibly also to further
distinguish the ‘driver’ mutations from the ‘passenger’ muta-
tions [2]. This can be established by means of molecular
sequencing of DNA from tumor biopsy specimens, determin-
ing which genetic or epigenetic alterations have developed at
the time of clinical appearance or the time of evidence of
drug resistance. Furthermore, multiple fusion genes that may
represent new therapeutic targets have been discovered in
various cancers as a consequence of the major advances and
availability of high throughput techniques such as whole-gen-
ome sequencing. However, interpretation and implementation
of the findings from the sequencing consortia will require
comprehensive multi-disciplinary efforts for translation into
the clinic.
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Present Challenges for Translating Promising Targets to
Successful Cancer Treatment
Comprehensive characterization of multiple tumor specimens
obtained from the same patient illustrates that the remarkable
intratumor heterogeneity might exist between distinct geo-
graphical regions within the same tumor, as well as between
the primary tumor and subsequent local or distant recurrence
in the same patient. Indeed, inter- and intratumor heterogeneity
poses a significant challenge to personalized cancer medicine
[53]. As previously discussed, intracellular crosstalk between
signaling pathways as seen with the RTKs AXL and EGFR,
dynamic signaling interactions between tumor cells and stro-
mal cells represent sophisticated mechanisms of drug resis-
tance [54]. Another mechanism of resistance may be seen in
the situation of intercellular crosstalk and paracrine signaling.
Furthermore, as seen in the situation of EGFRvIII, a tumor-
specific EGFR mutant has been shown to increase the tumori-
genecity of its neighbouring tumor cells by stimulating the
secretion of the pro-tumorigenic interleukins IL-6 and LIF
[55]. To overcome the issue of resistance, the challenge is to
design an optimal combination of targeted drugs. Moreover,
defining optimal therapeutic windows may be critical. It has
been hypothesized that various and specific niches within the
tumor, as well as in the surrounding tissue, contribute to main-
tain and enhance the plasticity of cancer cells. In this context,
it should be noted that the efficacy of a particular targeted
drug in the clinical setting is not solely dependent on the spe-
cific genetic make-up of the tumor cell population, but also
dependent on micro-environmental ability to sustain the differ-
ent tumor cell populations. This heterogeneity may also be
subject to selection and evolution of the developing tumor
upon treatment.
The key for unravelling the code for cancer development
may not be achieved solely by detailed sequencing of the can-
cer genome. Pinpointing genetic alterations and ‘driver’ muta-
tions may aid in defining the cancer cells, but in order to truly
understand the initiation and development of cancer, as well
as mechanisms involved in therapy resistance, we need to
focus on the interactions between the cancer cells and the
tumor micro-environment. To unravel the functional conse-
quences of intercellular communication and specific mutational
signatures on cellular signaling pathways in cancer, it is cru-
cial to develop model systems that truly recapitulate the dis-
ease. Accurately, modelling tumor complexity and
heterogeneity poses a significant challenge. Moreover, further
development of reproducible, yet complex and representative
tumor models both in vitro and in vivo is urgently needed.
Relevant Biomarkers in Targeted Cancer Therapy
Due to the significant cost and possible side effects of targeted
drugs, a new drug should ideally not be introduced to the mar-
ket without a reliable biomarker to predict which patients will
benefit from the treatment and which patients are at particu-
larly high risk of experiencing serious side effects of the drug.
The challenge may be to determine the right combination of
drugs or lines of therapy for different subtypes of cancer. In
this respect, and as previously mentioned, the data showing
that patients with colorectal cancer with KRAS mutations do
not benefit from treatment with Cetuximab, are setting the
stage for increased use of molecular diagnostics that could
guide oncologists to select the most effective treatment options
for their patients.
Importantly, the currently used models of clinical trials are
in most cases not suitable for evaluation of therapy tailored to
treat a single cancer patient or smaller groups of cancer
patients harbouring cancers with particular genetic alterations
in common. Optimal trial design is a pre-requisite for efficient
translation of novel drugs and represents a major challenge to
medical oncology, clinical trials and modern health care in
general. The success of combining a targeted drug with che-
motherapy has led to the hypothesis that efficacy could be
enhanced by adding several targeted agents [56], particularly
with regard to fight the mechanisms of treatment resistance.
Implementation of relevant biomarkers may assist in overcom-
ing the challenges involved in optimal design of clinical trials,
optimization of drug combinations, timing and dose regimens,
and may thus be an important step towards the goal of imple-
mentation of novel, targeted treatment regimens in the clinic.
Conclusions and Future Perspectives
‘Molecularly targeted cancer therapies have a short but rich his-
tory, an exciting present and a promising future’ [8]. Despite the
availability of improved drugs and new therapeutic strategies,
including targeted cancer therapies, cancer is still one of the
leading causes of death worldwide. However, due to novel tech-
nology and improved knowledge of the genetic and epigenetic
make-up of a particular cancer, cancer treatment may change
radically over the next few years. Never the less, the most prom-
inent clinical challenges in cancer treatment, namely metastatic
spread and development of therapy-resistant clones, are respon-
sible for most cancer-related deaths, and substantial multi-disci-
plinary efforts are required to overcome these hurdles.
Looking forward, perhaps the greatest promise comes from
the notion that re-educating a dysfunctional tumor micro-envi-
ronment could yield striking results in cancer control and
remission, as evidenced by the accumulating success stories in
the cancer immunotherapy field. Moreover, the discovery and
implementation of relevant biomarkers may assist substantially
in the development of targeted cancer therapy. Although more
research is warranted, the results recently achieved by targeted
cancer therapy efforts suggest that tailored therapy for most, if
not all, cancer patients may become a realistic approach in the
near future.
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